<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583321</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 054-15</org_study_id>
    <nct_id>NCT02583321</nct_id>
  </id_info>
  <brief_title>Detection of Chlorhexidine in Tracheal Secretions After Routine Oral Care With Chlorhexidine Gluconate</brief_title>
  <official_title>Detection of Chlorhexidine in Tracheal Secretions After Routine Oral Care With Chlorhexidine Gluconate: an Ancillary Study of the DEMETER Trial (NCT02515617)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent meta-analysis have suggested that the safety of oral care with chlorhexidine in
      patients under mechanical ventilation could be questionable. Whatever the hypothetical
      mechanisms involved (direct cellular toxicity, underdiagnosis of Ventilator-Associated
      Pneumonia), presence of chlorhexidine in tracheal secretions after routine oral care is the
      cornerstone of this potential side effect of the routine oral care with chlorhexidine
      gluconate. The DEMETER study assessing the medico-economical impact of the subglottic
      secretions drainage study (NCT02515617) provides the opportunity to perform this proof of
      concept study (detection of chlorhexidine in tracheal secretions after routine oral care with
      chlorhexidine gluconate) and to evaluate the impact of the subglottic secretion drainage on
      this potential detection of chlorhexidine.

      This ancillary study will be performed in one of the centers participating to the DEMETER
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with detection of chlorhexidine in tracheal secretions during the period without SSD</measure>
    <time_frame>Day 3 of mechanical ventilation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with detection of chlorhexidine in tracheal secretions during the period with SSD</measure>
    <time_frame>Day 3 of mechanical ventilation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of detection of chlorhexidine in tracheal secretions according to the study group.</measure>
    <time_frame>Day 28 of mechanical ventilation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with detection of chlorhexidine in subglottic secretions during the period with SSD</measure>
    <time_frame>Day 3 of mechanical ventilation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of detection of chlorhexidine in subglottic secretions during the SSD period.</measure>
    <time_frame>Day 28 of mechanical ventilation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chlorhexidine</condition>
  <condition>Intensive Care</condition>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes not allowing SSD</intervention_name>
    <description>In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30째-45째, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure</description>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes allowing SSD</intervention_name>
    <description>In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30째-45째, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.</description>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Invasive mechanical ventilation (MV) delivered via an endotracheal tube and MV
             required more than 72 hours

          -  Intubation performed in units in which the specific endotracheal tube allowing the
             subglottic secretions drainage (SSD) will be available during the SSD period of the
             trial

          -  Information delivered

        Exclusion Criteria:

          -  Previous inclusion in the study

          -  Patients moribund at the ICU admission

          -  Pregnant, parturient or breast-feeding woman

          -  Patient hospitalized without consent and/or deprived of liberty by court's decision

          -  Patient under guardianship or curators

          -  Lack of social insurance

          -  Concomitant inclusion in a trial on VAP prevention

          -  Patient with no comprehension of the French language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude LACHERADE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD VENDEE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertrand Diquet, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Claude LACHERADE, MD</last_name>
    <phone>33 2 51 44 60 87</phone>
    <email>jean-claude.lacherade@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHD Vendee</name>
      <address>
        <city>LA roche sur yon</city>
        <zip>85170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude Lacherade, MD</last_name>
      <phone>33 2 51 44 60 87</phone>
      <email>jean-claude.lacherade@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Claude Lacherade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Klompas M, Speck K, Howell MD, Greene LR, Berenholtz SM. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis. JAMA Intern Med. 2014 May;174(5):751-61. doi: 10.1001/jamainternmed.2014.359. Review.</citation>
    <PMID>24663255</PMID>
  </reference>
  <reference>
    <citation>Price R, MacLennan G, Glen J; SuDDICU Collaboration. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ. 2014 Mar 31;348:g2197. doi: 10.1136/bmj.g2197. Review.</citation>
    <PMID>24687313</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chlorhexidine gluconate</keyword>
  <keyword>oral care</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>critically ill patients</keyword>
  <keyword>tracheal secretions</keyword>
  <keyword>subglottic secretions</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

